These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 3499218

  • 1. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
    Talmadge JE, Phillips H, Schindler J, Tribble H, Pennington R.
    Cancer Res; 1987 Nov 01; 47(21):5725-32. PubMed ID: 3499218
    [Abstract] [Full Text] [Related]

  • 2. Preclinical approaches to the treatment of metastatic disease: therapeutic properties of rH TNF, rM IFN-gamma, and rH IL-2.
    Talmadge JE, Black PL, Tribble H, Pennington R, Bowersox O, Schneider M, Phillips H.
    Drugs Exp Clin Res; 1987 Nov 01; 13(6):327-37. PubMed ID: 3115744
    [Abstract] [Full Text] [Related]

  • 3. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Cancer Res; 1986 Jun 01; 46(6):2784-92. PubMed ID: 3486038
    [Abstract] [Full Text] [Related]

  • 4. Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice.
    Talmadge JE, Tribble HR, Pennington RW, Phillips H, Wiltrout RH.
    Cancer Res; 1987 May 15; 47(10):2563-70. PubMed ID: 3105865
    [Abstract] [Full Text] [Related]

  • 5. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, Ritz J.
    Clin Cancer Res; 1996 Mar 15; 2(3):493-9. PubMed ID: 9816195
    [Abstract] [Full Text] [Related]

  • 6. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
    Hornung RL, Back TC, Zaharko DS, Urba WJ, Longo DL, Wiltrout RH.
    J Immunol; 1988 Nov 15; 141(10):3671-9. PubMed ID: 2460546
    [Abstract] [Full Text] [Related]

  • 7. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 15; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
    Ohnishi H, Lin KM, Chu TM.
    Cancer Res; 1990 Feb 15; 50(4):1107-12. PubMed ID: 2297759
    [Abstract] [Full Text] [Related]

  • 15. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer.
    Okada K, Nannmark U, Vujanovic NL, Watkins S, Basse P, Herberman RB, Whiteside TL.
    Cancer Res; 1996 Apr 01; 56(7):1599-608. PubMed ID: 8603408
    [Abstract] [Full Text] [Related]

  • 16. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R, Rosenberg SA.
    Cancer Res; 1985 Aug 01; 45(8):3735-41. PubMed ID: 3893689
    [Abstract] [Full Text] [Related]

  • 17. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L.
    Cancer Res; 1995 Nov 01; 55(21):4941-9. PubMed ID: 7585534
    [Abstract] [Full Text] [Related]

  • 18. Immunomodulatory activity of a novel nucleoside, 7-thia-8-oxoguanosine: I. Activation of natural killer cells in mice.
    Sharma BS, Mhaskar S, Balazs L, Siaw M.
    Immunopharmacol Immunotoxicol; 1992 Nov 01; 14(1-2):1-19. PubMed ID: 1597650
    [Abstract] [Full Text] [Related]

  • 19. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
    Tomala J, Chmelova H, Mrkvan T, Rihova B, Kovar M.
    J Immunol; 2009 Oct 15; 183(8):4904-12. PubMed ID: 19801515
    [Abstract] [Full Text] [Related]

  • 20. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD, Browne CP, Layman NK, Riedl P, Tang J, Marder P, DeLong D, Manetta J, Bobbitt L, Strnad J.
    Cancer Res; 1988 Nov 01; 48(21):6081-9. PubMed ID: 3048654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.